Yana Gofman, DO
Internal Medicine · Davie, FLNPI 1902231863
Payments from drug & device makers
Across 42 payments — averaging $20.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$163
- GSK$157
- Exact Sciences$114
- Astellas Pharma US Inc$84
- Novo Nordisk$62
- Amgen$47
- plus $246 from 11 others
What the payments were for
- Food & beverage$873100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 8 | $163 |
| GSK | 8 | $157 |
| Exact Sciences | 5 | $114 |
| Astellas Pharma US Inc | 3 | $84 |
| Novo Nordisk | 4 | $62 |
| Amgen | 2 | $47 |
| Vanda Pharmaceuticals Inc. | 1 | $33 |
| AstraZeneca | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 1 | $29 |
| Edwards Lifesciences | 1 | $27 |
| Lundbeck LLC | 1 | $26 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
How this compares
$873 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $11,724 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 64 | $1,339 |
| Atorvastatin Calcium | 92 | $754 |
| Rosuvastatin Calcium | 46 | $590 |
| Levothyroxine Sodium | 76 | $557 |
| Nifedipine ErNifedipine | 17 | $462 |
| Gabapentin | 31 | $442 |
| Montelukast Sodium | 23 | $397 |
| Omeprazole | 36 | $333 |
| Pantoprazole Sodium | 29 | $331 |
| Fluticasone Propionate | 30 | $317 |
| Amlodipine Besylate | 52 | $315 |
| Trazodone Hcl | 27 | $291 |
| Carvedilol | 33 | $199 |
| Simvastatin | 17 | $184 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Davie
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.